I recently spent a fascinating few days as part of a European Commission group looking at the future of medical devices and drug delivery. Some may call this nanomedicine, but the association with nanobots, respirocytes and replacing perfectly good bits of the body that have been road tested over millennia with new materials just for the sake of it wasnt really on the agenda.
As a large part of my current workload involves looking at the financial and economic implications of nanotechnology (hence the silence in this column), with drug delivery and medical devices being two of the lowest hanging fruits, there wasnt too much to learn about the technology that hadnt already been covered. However, the two areas of real interest, especially to business, were regulation and toxicology.
You can read the full story over on Nanotechweb